V网曝门 obesity drugmaker Lilly has announced a 拢279m ($365.5m) investment in the UK in a major collaboration between the company and the UK government. The announcement was made during October 2024’s International Investment Summit in London, emphasising the UK鈥檚 ambition to remain at the forefront of life sciences innovation.
A cornerstone of the investment is the launch of Europe鈥檚 first Lilly Gateway Labs, an innovation accelerator designed to support early-stage life science ventures. The facility will offer advanced laboratory space, mentorship and financial support to help startups develop transformative medicines. The initiative aims to further enhance the growth of the life sciences sector, which already contributes to the UK economy, supporting 300,000 jobs.
Obesity costs the National Health Service (NHS) more than 拢11bn annually and as the country’s second leading preventable cause of cancer, is a central focus of the collaboration. The partnership seeks to explore innovative treatments and technologies to address this health issue. David A Ricks, chair and CEO of Eli Lilly and Company, emphasised the importance of this initiative, highlighting its role in 鈥渢ackling and preventing disease, and accelerating innovation to advance care delivery models.鈥� He noted that the collaboration between the government and Lilly reinforces Lilly鈥檚 commitment to improving the lives of those affected by obesity and its serious consequences. By integrating life sciences expertise with the healthcare system, the initiative seeks to deliver improved long-term health outcomes for patients.
The UK government has positioned life sciences as a central pillar of its economic growth strategy, with this initiative further reinforcing that commitment. Speaking at the summit, Science and Technology Secretary Peter Kyle stated that the collaboration will drive the economy and contribute to 鈥渃reating the jobs, opportunity and growth we need to invest further in health and to push up living standards.鈥�
The announcement aligns with the UK government鈥檚 strategy to strengthen the NHS, outlined in the Autumn Budget 2024. An additional 拢25.7bn – the largest funding boost since 2010, excluding the Covid-19 periods – will be allocated up to 2026. Key measures include reducing waiting times for medical treatment with 40,000 extra weekly elective appointments and ensuring treatment within 18 weeks of referral. The plan also dedicates 拢1.5bn to new surgical hubs for 30,000 additional procedures annually, and supports more than 1.25 million advanced diagnostic tests. These investments address immediate challenges while building long-term resilience in the healthcare system.
Lilly鈥檚 investment and the UK government鈥檚 strategic support for life sciences and healthcare represent a pivotal moment for the industry. By fostering innovation, addressing pressing health challenges such as obesity and driving economic growth, the collaboration sets a powerful example of public-private partnerships aimed at improving both national health outcomes and economic advancements.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData